Provided by Tiger Trade Technology Pte. Ltd.

Merck

149.02
+1.260.85%
Volume:2.91M
Turnover:435.85M
Market Cap:367.66B
PE:117.08
High:151.68
Open:150.23
Low:148.94
Close:147.76
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.70
T/O Rate:0.12%
Dividend:3.32
Dividend Rate:2.23%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.77
PE(LYR):20.47

Loading ...

Bio-Techne Surges as Merck Agrees to Acquire Company at $73 Per Share in Cash

Market Focus
·
Jun 25

Merck Gains FDA Approval for Keytruda Plus Trodelvy in PD-L1 Positive Breast Cancer

MT Newswires Live
·
Jun 25

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

TIPRANKS
·
Jun 25

FDA Approves Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and Berahyaluronidase Alfa-pmph), Each with Trodelvy® (sacituzumab Govitecan-hziy) as First-line Treatment of Pd-l1+ (CPS ≥10) Advanced Triple-negative Breast Cancer (tnbc)

THOMSON REUTERS
·
Jun 25

Alerts Incorrectly Tagged to Merck & Co Withdrawn

Reuters
·
Jun 25

Major Deals Involving US Drugmakers and Biotechs over the Past Decade

Reuters
·
Jun 25

Germany's Merck Boosts Life Sciences Business with $11 Billion Bet on Bio-techne

Reuters
·
Jun 25

Merck Reviews Regional Distribution Hub Plan In Abu Dhabi

MT Newswires Live
·
Jun 25

Department of Health Abu Dhabi: Partnership with Msd to Advance Operational Excellence and Expand Access Across Region

THOMSON REUTERS
·
Jun 25

Merck Initiated at Outperform by CICC

Dow Jones
·
Jun 25

Unicef, Gavi Call to Speed Bundibugyo Ebola Vaccine Access

Reuters
·
Jun 25

Merck says EC approves Keytruda plus Padcev combination

TIPRANKS
·
Jun 24

EU Approves Merck Keytruda Plus Padcev for Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

Reuters
·
Jun 24

European Commission Approves Keytruda® (pembrolizumab) Plus Padcev® (enfortumab Vedotin-ejfv) as First Pd-1 Inhibitor Plus Antibody-drug Conjugate Regimen for Adults with Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

THOMSON REUTERS
·
Jun 24

PharmaMar’s Partner Merck Seeks Priority Approval in Japan for Zepzelca as First-Line SCLC Maintenance

TIPRANKS
·
Jun 24

CICC Initiates Merck & Co. at Outperform With $138 Price Target

MT Newswires Live
·
Jun 24

Merck initiated with an Outperform at CICC

TIPRANKS
·
Jun 24

Movement Alert|Merck Rises 3.03% in Regular Trading, Multiple Catalysts Including Phase 3 Trial Success and Potential Major Acquisition

Market Focus
·
Jun 24

Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Citi Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23